275 related articles for article (PubMed ID: 27528032)
1. miR-31 targets ARID1A and enhances the oncogenicity and stemness of head and neck squamous cell carcinoma.
Lu WC; Liu CJ; Tu HF; Chung YT; Yang CC; Kao SY; Chang KW; Lin SC
Oncotarget; 2016 Aug; 7(35):57254-57267. PubMed ID: 27528032
[TBL] [Abstract][Full Text] [Related]
2. Acquisition cancer stemness, mesenchymal transdifferentiation, and chemoresistance properties by chronic exposure of oral epithelial cells to arecoline.
Wang TY; Peng CY; Lee SS; Chou MY; Yu CC; Chang YC
Oncotarget; 2016 Dec; 7(51):84072-84081. PubMed ID: 27557511
[TBL] [Abstract][Full Text] [Related]
3. Co-targeting of multiple microRNAs on factor-Inhibiting hypoxia-Inducible factor gene for the pathogenesis of head and neck carcinomas.
Kao SY; Tsai MM; Wu CH; Chen JJ; Tseng SH; Lin SC; Chang KW
Head Neck; 2016 Apr; 38(4):522-8. PubMed ID: 25351569
[TBL] [Abstract][Full Text] [Related]
4. The role of HOXB9 and miR-196a in head and neck squamous cell carcinoma.
Darda L; Hakami F; Morgan R; Murdoch C; Lambert DW; Hunter KD
PLoS One; 2015; 10(4):e0122285. PubMed ID: 25860510
[TBL] [Abstract][Full Text] [Related]
5. miR-134 induces oncogenicity and metastasis in head and neck carcinoma through targeting WWOX gene.
Liu CJ; Shen WG; Peng SY; Cheng HW; Kao SY; Lin SC; Chang KW
Int J Cancer; 2014 Feb; 134(4):811-21. PubMed ID: 23824713
[TBL] [Abstract][Full Text] [Related]
6. Antitumor miR-150-5p and miR-150-3p inhibit cancer cell aggressiveness by targeting SPOCK1 in head and neck squamous cell carcinoma.
Koshizuka K; Hanazawa T; Kikkawa N; Katada K; Okato A; Arai T; Idichi T; Osako Y; Okamoto Y; Seki N
Auris Nasus Larynx; 2018 Aug; 45(4):854-865. PubMed ID: 29233721
[TBL] [Abstract][Full Text] [Related]
7. Activation of microRNA-494-targeting Bmi1 and ADAM10 by silibinin ablates cancer stemness and predicts favourable prognostic value in head and neck squamous cell carcinomas.
Chang YC; Jan CI; Peng CY; Lai YC; Hu FW; Yu CC
Oncotarget; 2015 Sep; 6(27):24002-16. PubMed ID: 26090866
[TBL] [Abstract][Full Text] [Related]
8. Dual-receptor (EGFR and c-MET) inhibition by tumor-suppressive miR-1 and miR-206 in head and neck squamous cell carcinoma.
Koshizuka K; Hanazawa T; Fukumoto I; Kikkawa N; Matsushita R; Mataki H; Mizuno K; Okamoto Y; Seki N
J Hum Genet; 2017 Jan; 62(1):113-121. PubMed ID: 27169691
[TBL] [Abstract][Full Text] [Related]
9. Dysregulation of microRNA-34a expression in head and neck squamous cell carcinoma promotes tumor growth and tumor angiogenesis.
Kumar B; Yadav A; Lang J; Teknos TN; Kumar P
PLoS One; 2012; 7(5):e37601. PubMed ID: 22629428
[TBL] [Abstract][Full Text] [Related]
10. CK2 phosphorylates and inhibits TAp73 tumor suppressor function to promote expression of cancer stem cell genes and phenotype in head and neck cancer.
Lu H; Yan C; Quan XX; Yang X; Zhang J; Bian Y; Chen Z; Van Waes C
Neoplasia; 2014 Oct; 16(10):789-800. PubMed ID: 25379016
[TBL] [Abstract][Full Text] [Related]
11. miR145 targets the SOX9/ADAM17 axis to inhibit tumor-initiating cells and IL-6-mediated paracrine effects in head and neck cancer.
Yu CC; Tsai LL; Wang ML; Yu CH; Lo WL; Chang YC; Chiou GY; Chou MY; Chiou SH
Cancer Res; 2013 Jun; 73(11):3425-40. PubMed ID: 23548270
[TBL] [Abstract][Full Text] [Related]
12. A Study on the Correlations of the miR-31 Expression with the Pathogenesis and Prognosis of Head and Neck Squamous Cell Carcinoma.
Qiang H; Zhan X; Wang W; Cheng Z; Ma S; Jiang C
Cancer Biother Radiopharm; 2019 Apr; 34(3):189-195. PubMed ID: 30628842
[TBL] [Abstract][Full Text] [Related]
13. miR-34a-5p functions as a tumor suppressor in head and neck squamous cell cancer progression by targeting Flotillin-2.
Li X; Zhao S; Fu Y; Zhang P; Zhang Z; Cheng J; Liu L; Jiang H
Int J Biol Sci; 2021; 17(15):4327-4339. PubMed ID: 34803501
[TBL] [Abstract][Full Text] [Related]
14. Loss of SOX2 expression induces cell motility via vimentin up-regulation and is an unfavorable risk factor for survival of head and neck squamous cell carcinoma.
Bayo P; Jou A; Stenzinger A; Shao C; Gross M; Jensen A; Grabe N; Mende CH; Rados PV; Debus J; Weichert W; Plinkert PK; Lichter P; Freier K; Hess J
Mol Oncol; 2015 Oct; 9(8):1704-19. PubMed ID: 26040981
[TBL] [Abstract][Full Text] [Related]
15. Blockade of deubiquitinating enzyme PSMD14 overcomes chemoresistance in head and neck squamous cell carcinoma by antagonizing E2F1/Akt/SOX2-mediated stemness.
Jing C; Duan Y; Zhou M; Yue K; Zhuo S; Li X; Liu D; Ye B; Lai Q; Li L; Yao X; Wei H; Zhang W; Wu Y; Wang X
Theranostics; 2021; 11(6):2655-2669. PubMed ID: 33456565
[TBL] [Abstract][Full Text] [Related]
16. Wnt/β-catenin signalling maintains self-renewal and tumourigenicity of head and neck squamous cell carcinoma stem-like cells by activating Oct4.
Lee SH; Koo BS; Kim JM; Huang S; Rho YS; Bae WJ; Kang HJ; Kim YS; Moon JH; Lim YC
J Pathol; 2014 Sep; 234(1):99-107. PubMed ID: 24871033
[TBL] [Abstract][Full Text] [Related]
17. miR-204 inhibits angiogenesis and promotes sensitivity to cetuximab in head and neck squamous cell carcinoma cells by blocking JAK2-STAT3 signaling.
Wu Q; Zhao Y; Wang P
Biomed Pharmacother; 2018 Mar; 99():278-285. PubMed ID: 29353201
[TBL] [Abstract][Full Text] [Related]
18. MicroRNA-211 Enhances the Oncogenicity of Carcinogen-Induced Oral Carcinoma by Repressing TCF12 and Increasing Antioxidant Activity.
Chen YF; Yang CC; Kao SY; Liu CJ; Lin SC; Chang KW
Cancer Res; 2016 Aug; 76(16):4872-86. PubMed ID: 27221705
[TBL] [Abstract][Full Text] [Related]
19. Mir-144-3p Promotes Cell Proliferation, Metastasis, Sunitinib Resistance in Clear Cell Renal Cell Carcinoma by Downregulating ARID1A.
Xiao W; Lou N; Ruan H; Bao L; Xiong Z; Yuan C; Tong J; Xu G; Zhou Y; Qu Y; Hu W; Gao Y; Ru Z; Liu L; Xiao H; Chen K; Yang H; Zhang X
Cell Physiol Biochem; 2017; 43(6):2420-2433. PubMed ID: 29073615
[TBL] [Abstract][Full Text] [Related]
20. Effect of 3q oncogenes SEC62 and SOX2 on lymphatic metastasis and clinical outcome of head and neck squamous cell carcinomas.
Bochen F; Adisurya H; Wemmert S; Lerner C; Greiner M; Zimmermann R; Hasenfus A; Wagner M; Smola S; Pfuhl T; Bozzato A; Al Kadah B; Schick B; Linxweiler M
Oncotarget; 2017 Jan; 8(3):4922-4934. PubMed ID: 28002801
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
